RMD ResMed Inc
- 36.810
- -0.120-0.32%
ResMed Inc News
ResMed Initiated at Hold by Stifel
ResMed Price Target Announced at $250.00/Share by Stifel
J.P. Morgan Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
ResMed Is Maintained at Outperform by Baird
ResMed Price Target Raised 4.3% to A$37.80/Share by Macquarie
ResMed Is Maintained at Buy by B of A Securities
ResMed Initiated at Outperform by Baird
ResMed Price Target Announced at $180.00/Share by Wolfe Research
ResMed Cut to Underperform From Peer Perform by Wolfe Research
Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (AU:RMD) and Bayer (GB:0P6S)
ResMed Price Target Maintained With a $236.00/Share by Needham
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgans Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
ResMed Price Target Raised to $251.00/Share From $238.00 by Keybanc
ResMed Price Target Maintained With a $236.00/Share by Needham
Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD) Receives a Hold From Citi
ResMed Price Target Raised 1.6% to A$35.40/Share by Macquarie
ResMed Price Target Raised to $204.00/Share From $200.00 by RBC Capital
Analysts Offer Insights on Healthcare Companies: Novartis AG (Six Swiss: CH:NOVN), Carl Zeiss Meditec (GB:0DHC) and Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (AU:RMD)
Morgan Stanley Adjusts Resmed's Price Target to AU$31.80 From AU$28.60, Keeps at Overweight
No Data